chemotherapi
protozo
infect
continu
caus
advers
effect
dose
normal
therapeut
index
literatur
search
pubm
articl
review
alreadi
publish
data
onlin
pharmaceut
databas
present
content
includ
year
chapter
inclus
combin
trimethoprimsulfamethoxazol
thiamin
nonantiprotozo
therapi
requir
agent
use
two
clinic
trial
treat
protozo
infect
use
combin
therapi
correl
increas
advers
event
recur
theme
year
investig
make
advanc
treatment
protozo
infect
phase
ii
result
fexinidazol
includ
chapter
howev
current
fda
approv
unit
state
methyl
n
carbam
albendazol
benzimidazol
anthelmint
agent
commonli
use
treatment
echinococcosi
also
known
hydatid
cyst
neurocysticercosi
caus
degen
alter
tegument
intestin
worm
lead
impair
uptak
glucos
caus
deplet
glycogen
store
albendazol
ultim
caus
decreas
product
atp
caus
immobil
death
worm
investig
recent
trial
evalu
effect
combin
therapi
praziquantel
albendazol
mgkgday
mgkgday
respect
comparison
two
differ
dose
albendazol
mgkgday
treatment
neurocysticercosi
praziquantel
also
anthelmint
work
caus
strong
contract
within
parasit
caus
paralysi
eventu
dislodg
purpos
studi
determin
combin
two
differ
mechan
would
effect
singl
agent
therapi
also
note
past
praziquantel
increas
serum
concentr
activ
metabolit
albendazol
side
effect
list
studi
describ
seizur
headach
pregnanc
druginduc
hepat
includ
spontan
abort
urinari
tract
infect
motor
vehicl
accid
dizzi
fever
vomit
intracrani
hypertens
side
effect
group
except
druginduc
hepat
common
increas
dose
albendazol
combin
therapi
standard
albendazol
therapi
studi
found
increas
preval
advers
effect
statist
signific
current
list
interact
albendazol
praziquantel
activ
ingredi
birth
control
methylen
artemeth
semisynthet
deriv
artemisinin
natur
occur
sesquiterpen
lacton
obtain
chines
herb
artemisia
annua
qing
hao
lumefantrin
antimalari
agent
initi
develop
china
treatment
plasmodium
falciparum
mediat
malaria
synthet
racem
fluoren
deriv
dichlorobenzylidin
broad
schizontocid
activ
conform
structur
physiochem
mechanist
aryl
amino
alcohol
group
antimalari
agent
eg
halofantrin
mefloquin
quinin
open
random
control
clinic
trial
compar
efficaci
safeti
three
artemisininbas
combin
incid
labial
herp
occur
combin
artemetherlumefantrin
dose
mg
respect
labial
herp
also
call
fever
blister
cold
sore
caus
herp
simplex
viru
type
viru
lie
latent
dormant
bodi
reawaken
reactiv
factor
stress
sunburn
fever
wide
rang
infecti
diseas
includ
cold
median
age
affect
year
thought
advers
event
report
due
combin
artemetherlumefantrin
instead
transmit
child
rub
sore
touch
anoth
person
andor
kiss
dihydroartemisinin
piperaquin
propan
dihydroartemisininpiperaquin
antimalari
combin
drug
metaanalysi
includ
studi
compar
dihydroartemisininpiperaquin
dhap
artemisininbas
combin
therapi
act
found
dhap
patient
experi
less
side
effect
palpit
sleepless
dizzi
vomit
nausea
howev
low
qualiti
evid
indic
dhap
could
associ
higher
frequenc
qtc
interv
prolong
fexinidazol
may
use
treatment
stage
human
african
trypanosomiasi
sleep
sick
spread
bite
tsets
fli
carri
either
trypanosoma
brucei
gambiens
trypanosoma
brucei
rhodesiens
studi
complet
order
determin
toler
varieti
differ
dosag
formul
total
healthi
male
use
studi
headach
commonli
report
advers
event
follow
vomit
nausea
diarrhea
less
common
advers
event
includ
gastroesophag
reflux
diseas
abdomin
pain
dizzi
flush
increas
transaminas
somnol
regurgit
fever
palpit
sweat
insomnia
paresthesia
myalgia
kerat
chest
pain
dysuria
asthenia
anxieti
dyspepsia
fumagillin
antibiot
activ
microsporidi
infect
act
inhibit
rna
synthesi
microsporidia
oblig
intracellular
sporeform
protozoan
parasit
acquir
multipl
pathway
ingest
inhal
direct
contact
conjunctiva
anim
contact
persontoperson
transmiss
heavili
associ
individu
human
immunodefici
viru
one
review
fumagillin
note
signific
bone
marrow
toxic
defin
occur
patient
receiv
mg
oral
daili
week
effect
resolv
within
day
treatment
cessat
nitazoxanid
antiprotozo
agent
commonli
use
treatment
diarrhea
caus
cryptosporidium
parvum
giardia
lamblia
also
use
treat
clostridium
difficil
infect
believ
nitazoxanid
work
interfer
pyruv
ferredoxin
oxireductas
pfor
enzymedepend
electron
transfer
reaction
essenti
anaerob
metabol
clostridium
giardia
found
almost
surfac
water
found
extrem
resist
disinfect
commonli
use
make
water
drinkabl
order
effect
protect
popul
organ
filtrat
drinkingwat
requir
even
small
amount
organ
caus
infect
also
shown
nitazoxanid
may
effect
treatment
virus
includ
influenza
parainfluenza
coronaviru
respiratori
syncyti
viru
inhibit
viral
replic
use
togeth
neuraminidas
inhibitor
cell
nitazoxanid
provid
synergist
effect
recent
random
clinic
trial
examin
efficaci
nitazoxanid
two
differ
dose
treatment
acut
uncompl
influenza
patient
report
varieti
differ
advers
event
throughout
cours
treatment
advers
effect
like
rule
due
fact
patient
treat
influenza
includ
rhinorrhea
nasal
congest
sore
throat
cough
headach
myalgia
fatigu
pyrexia
sweatschil
other
bronchiti
sinus
otiti
may
rule
complic
influenza
howev
nitazoxanid
caus
infect
advers
event
report
particip
nitazoxanid
group
uncommon
report
particip
includ
diarrhea
oropharyng
pain
abdomin
pain
vomit
abnorm
liver
function
test
otiti
media
constip
dri
mouth
nasopharyng
chromaturia
report
patient
receiv
nitazoxanid
patient
receiv
advers
event
common
least
one
nitazoxanid
treatment
group
compar
placebo
commonli
associ
influenza
adult
although
albendazol
drug
choic
hookworm
show
low
efficaci
treat
trichuria
helminth
transmit
soil
clinic
studi
involv
patient
includ
incid
one
child
receiv
combin
oxantel
pamoat
albendazol
case
fever
diarrhea
within
hour
administr
case
may
isol
worth
mention
rare
possibl
interact
posaconazol
ergosterol
inhibitor
triazol
antifung
medic
commonli
use
candida
asperigillu
also
use
chaga
diseas
also
known
american
trypanosomiasi
caus
cruzi
parasit
spread
lymphat
system
vasculatur
eventu
accumul
muscl
ganglion
cell
commonli
infect
heart
posaconazol
known
caus
inflamm
mucos
tissu
call
mucos
mucos
often
associ
chemotherapi
also
result
use
ergosterol
inhibitor
like
posaconazol
incid
report
regard
possibl
develop
mucos
like
lead
dryness
mucos
tissu
random
trial
test
efficaci
posaconazol
treatment
chronic
chaga
diseas
involv
patient
studi
arm
author
note
mucos
dryness
approxim
patient
take
high
dose
posaconazol
patient
take
low
dose
author
found
posaconazol
ineffect
treatment
chaga
diseas
could
potenti
use
suppress
agent
use
adjunct
therapi
antitrypanosom
treatment
primaquin
aminoquinolin
use
treatment
plasmodium
falciparum
p
vivax
malaria
prevent
relaps
p
vivax
malaria
treatment
work
erad
infect
present
tissu
prevent
relaps
elimin
parasit
present
blood
p
vivax
resist
treatment
p
falciparum
due
varieti
reason
includ
p
vivax
dormant
liver
stage
difficult
kill
earlier
appear
gametocyt
infect
toler
sporogon
cycl
low
temperatur
current
treatment
primaquin
effect
kill
p
vivax
dormant
stage
make
primaquin
best
option
treatment
p
vivax
use
often
risk
acut
hemolyt
anemia
patient
dehydrogenas
defici
review
articl
compil
inform
four
differ
studi
date
late
mass
distribut
primaquin
popul
high
preval
defici
overal
found
primaquin
rel
well
toler
especi
taken
food
around
patient
experienc
side
effect
headach
epigastr
pain
nausea
vomit
dizzi
anorexia
chromaturia
black
urin
possibl
symptom
hemolyt
anemia
studi
complet
korea
found
treat
popul
experienc
black
urin
despit
higher
preval
defici
studi
conduct
azerbaijan
afghanistan
report
patient
experienc
chang
urin
color
mani
patient
azerbaijan
afghanistan
mediterranean
variant
commonli
associ
sever
hemolyt
reaction
receiv
primaquin
studi
conduct
tajikistan
report
specif
advers
effect
state
combin
four
studi
treat
million
peopl
report
case
seriou
advers
effect
none
result
hospit
death
quinacrin
rs
n
n
prion
infecti
proteinac
particl
thought
caus
creutzfeldjakob
diseas
transmiss
spongiform
encephalopathi
quinacrin
antiprotozo
drug
also
known
inhibitori
effect
prion
format
one
studi
look
inhibitori
effect
prion
treatment
creutzfeldjakob
diseas
studi
enrol
patient
random
compar
quinacrin
vs
placebo
studi
found
quinacrin
improv
surviv
patient
creutzfeldjacob
diseas
within
first
two
month
one
case
sever
gastrointestin
distress
patient
receiv
quinacrin
elev
liver
function
test
gastrointestin
distress
commonli
report
advers
event
patient
quinacrin
group
initi
two
month
treatment
n
trifluoromethyl
phenoxi
rs
n
n
tafenoquin
synthet
analog
primaquin
around
awhil
enter
phase
iii
trial
treatment
prevent
relaps
case
plasmodium
vivax
malaria
detect
studi
evalu
use
tafenoquin
use
concurr
chloroquin
gather
studi
anticip
compar
tafenoquin
versu
primaquin
introduc
determin
end
point
safeti
efficaci
toler
incid
hemolysi
tafenoquin
current
approv
use
grant
breakthrough
statu
fda
expedit
process
like
primaquin
tafenoquin
caus
dehydrogenas
defici
patient
experi
advers
effect
hemolysi
test
defici
thu
warrant
prior
tafenoquin
administr
studi
healthi
subject
common
side
effect
includ
nausea
vomit
diarrhea
abdomin
pain
headach
dizzi
one
patient
event
may
indic
declin
visual
acuiti
potenti
effect
spontan
resolv
studi
also
indic
applic
site
eros
ekg
sticker
place
studi
also
found
advers
effect
qtc
prolong
clinic
insignific
administ
combin
chloroquin
detect
trial
phase
studi
safeti
toler
combin
chloroquin
tafenoquin
dose
rang
mg
treat
p
vivax
studi
enrol
patient
report
advers
event
notabl
patient
studi
defici
none
experienc
hemolysi
result
posit
studi
would
need
consid
remov
hemolysi
potenti
threat
defici
patient
tafenoquin
advers
event
tafenoquin
plu
chloroquin
group
differ
chloroquin
alon
group
includ
headach
vs
chill
vs
pyrexia
vs
nausea
vs
asthenia
vs
dizzi
vs
case
asthenia
thought
reaction
may
drug
relat
investig
abl
make
associ
qtc
prolong
tafenoquin
howev
defin
qtc
prolong
ms
advers
effect
may
attribut
use
drug
also
sign
diseas
state
treat
sinc
malari
infect
caus
headach
fever
well
vomit
n
n
formamid
hydrochlorid
monohydr
thiamin
hydrochlorid
convert
activ
coenzym
thiamin
pyrophosph
enzym
thiamin
diphosphokinas
thiamin
pyrophosph
function
carbohydr
metabol
decarboxyl
alphaketo
acid
hexos
monophosph
shunt
random
doubl
blind
parallel
placebo
control
trial
treatment
falciparum
malaria
southern
lao
util
oral
thiamin
hydrochlorid
supplement
daili
day
follow
standard
antimalari
care
daili
addit
day
determin
thiamin
would
decreas
number
advers
event
experienc
patient
receiv
antimalari
treatment
random
particip
subject
consid
biochem
thiamin
defici
three
percent
particip
receiv
thiamin
experienc
diarrhea
point
day
treatment
thiamin
experienc
dizzi
first
day
thiamin
supplement
doxycyclin
interfer
third
stage
bacteri
protein
synthesi
amino
acid
activ
attach
trna
transfer
rna
result
amino
acyltrna
migrat
bacteri
ribosom
synthesi
protein
doxycyclin
bind
subunit
ribosom
inhibit
bind
aminoacyltrna
molecul
trimethoprimsulfamethoxazol
use
treatment
pneumocysti
carinii
infect
call
pneumocysti
jirovecii
yeastlik
fungu
consid
protozoan
past
caus
pulmonari
diseas
immunocompromis
patient
act
inhibit
folic
acid
synthesi
melioidosi
also
known
whitmor
diseas
infect
caus
bacteria
burkholderia
pseudomallei
pathogen
genu
pseudomona
known
affect
human
anim
multicent
doubl
blind
noninferior
random
clinic
trial
compar
trimethoprimsulfamethoxazol
trimethoprimsulfamethoxazol
plu
doxycyclin
treatment
melioidosi
three
patient
experienc
nail
bed
chang
advers
effect
combin
therapi
trimethoprimsulfamethoxazol
administ
via
weightbas
dose
along
doxycyclin
mg
twenti
week
five
locat
northeast
thailand
p
aeruginosa
paronychia
correl
frequent
placement
hand
water
countri
discolor
result
diffus
pyocyanin
nail
bed
therefor
interact
trimethoprimsulfamethoxazol
combin
doxycyclin
like
artesun
hydrogen
succin
artesun
water
solubl
deriv
artemisinin
use
treat
plasmodium
falciparum
malaria
consid
firstlin
therapi
believ
work
creat
free
radic
cleav
portion
endoperoxid
bridg
may
also
damag
effect
catp
protein
fold
lexicomp
artesun
combin
antimalari
drug
avoid
resist
develop
refer
act
artmisininbas
combin
therapi
one
combin
artesunatemefloquin
therapi
mefloquin
work
destroy
asexu
blood
form
malaria
open
label
singlearm
studi
team
valecha
et
al
evalu
pharmacodynam
safeti
efficaci
artesunatemefloquin
combin
therapi
uncompl
malaria
caus
plasmodium
falciparum
small
studi
patient
rang
age
year
old
cure
rate
nearli
ci
valecha
et
al
report
potenti
advers
effect
take
combin
artesunatemefloquin
therapi
includ
toothach
pallor
anemia
among
known
advers
effect
though
find
may
seem
new
author
could
determin
advers
effect
directli
relat
drug
combin
rule
state
advers
event
record
one
could
logic
associ
drug
combin
gastriti
diarrhea
overal
combin
therapi
well
toler
patient
popul
r
trifluoromethyl
methanol
indic
mefloquin
hydrochlorid
mefloquinesuscept
p
falciparum
p
vivax
infect
may
caus
mild
moder
acut
malaria
malari
infect
caus
p
falciparum
p
vivax
may
prevent
prophylact
use
mefloquin
hydrochlorid
mefloquin
hydrochlorid
link
neurolog
side
effect
dizzi
tinnitu
balanc
problem
psychiatr
side
effect
hallucin
feel
anxious
depress
mistrust
five
year
studi
conduct
denmark
examin
psychiatr
advers
event
associ
use
mefloquin
patient
report
possibl
psychiatr
side
effect
assess
tool
use
studi
found
clinic
signific
anxieti
phobic
anxieti
depress
patient
receiv
mefloquin
studi
found
women
experienc
hallucin
often
men
studi
also
found
neurolog
side
effect
becom
long
term
sometim
even
perman
side
effect
result
fda
issu
black
box
warn
neurolog
psychiatr
side
effect
patient
develop
neurolog
psychiatr
symptom
take
mefloquin
prevent
malaria
patient
discuss
symptom
physician
physician
consid
discontinu
use
mefloquin
use
altern
drug
studi
stienlauf
et
al
design
examin
interact
chronic
medic
use
treatment
preexist
diseas
state
medic
use
prophylaxi
patient
travel
develop
countri
studi
retrospect
cohort
evalu
mefloquin
primaquin
doxycyclin
atovaquoneproguanil
fluoroquinolon
antibiot
rifaximin
azithromycin
acetazolamid
determin
interact
chronic
medic
larg
studi
individu
fluoroquinolon
well
azithromycin
shown
commonli
drugdrug
interact
chronic
medic
studi
subject
given
prevent
medic
interact
least
one
chronic
medic
interact
identifi
individu
commonli
attribut
use
acetazolamid
primaquin
mefloquin
also
note
presenc
drug
allergi
patient
take
acetazolamid
studi
experienc
drug
allergi
studi
need
verifi
result
clinician
awar
interact
medicin
use
travel
chronic
condit
andor
mainten
medic
